These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10803683)

  • 1. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.
    Miners JO; Coulter S; Birkett DJ; Goldstein JA
    Pharmacogenetics; 2000 Apr; 10(3):267-70. PubMed ID: 10803683
    [No Abstract]   [Full Text] [Related]  

  • 2. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
    Miners JO; Rees DL; Valente L; Veronese ME; Birkett DJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1076-81. PubMed ID: 7891318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM; Verhoeven CH; Shimada T; Back DJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cytochrome P450 2C9 activity in vitro by 5-hydroxytryptamine and adrenaline.
    Gervasini G; Martínez C; Agúndez JA; García-Gamito FJ; Benítez J
    Pharmacogenetics; 2001 Feb; 11(1):29-37. PubMed ID: 11207028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H; Inoue K; Shimada T
    Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C.
    Hamman MA; Thompson GA; Hall SD
    Biochem Pharmacol; 1997 Jul; 54(1):33-41. PubMed ID: 9296349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential inhibitory effects of phenytoin, diclofenac, phenylbutazone and a series of sulfonamides on hepatic cytochrome P4502C activity in vitro, and correlation with some molecular descriptors in the dwarf goat (Caprus hircus aegagrus).
    Zweers-Zeilmaker WM; Horbach GJ; Witkamp RF
    Xenobiotica; 1997 Aug; 27(8):769-80. PubMed ID: 9293615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
    Taguchi K; Konishi T; Nishikawa H; Kitamura S
    Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
    Miners JO; Birkett DJ
    Br J Clin Pharmacol; 1998 Jun; 45(6):525-38. PubMed ID: 9663807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
    Bourrié M; Meunier V; Berger Y; Fabre G
    Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes.
    Ren S; Yang JS; Kalhorn TF; Slattery JT
    Cancer Res; 1997 Oct; 57(19):4229-35. PubMed ID: 9331082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
    Baldwin SJ; Clarke SE; Chenery RJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):424-32. PubMed ID: 10510156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily.
    Lewis DF; Dickins M; Weaver RJ; Eddershaw PJ; Goldfarb PS; Tarbit MH
    Xenobiotica; 1998 Mar; 28(3):235-68. PubMed ID: 9574814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
    Hyland R; Roe EG; Jones BC; Smith DA
    Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population.
    Zarza J; Hermida J; Montes R; Alberca I; López ML; Rocha E
    Blood; 2002 Jul; 100(2):734. PubMed ID: 12123234
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.
    Ha-Duong NT; Dijols S; Marques-Soares C; Minoletti C; Dansette PM; Mansuy D
    J Med Chem; 2001 Oct; 44(22):3622-31. PubMed ID: 11606127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
    Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
    Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.